MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
42.19
-0.06 (-0.14%)
At close: Apr 19, 2024, 4:00 PM
40.81
-1.38 (-3.27%)
After-hours: Apr 19, 2024, 6:49 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Dr. Jorge Santos da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, V8 6300 Switzerland | |
| Phone | 41 41 510 8022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, Chief Executive Officer and Director |
| Dr. Kristian Reich | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop | Chief Technical Officer |
| Nicolas Mosimann | General Counsel |
| Luciana Marques | Director of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2024 | 8-K | Current Report |
| Mar 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 29, 2024 | 10-K | Annual Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 144 | Filing |
| Feb 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | 144 | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |